Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.

Study to Evaluate the Effect of Solifenacin and Mirabegron on the Digoxin Concentrations in Blood in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02127034
Recruitment Status : Completed
First Posted : April 30, 2014
Last Update Posted : July 11, 2014
Sponsor:
Information provided by (Responsible Party):
Astellas Pharma Inc ( Astellas Pharma Europe B.V. )

Brief Summary:
The purpose of this study is to evaluate the effect of steady state solifenacin and mirabegron on the pharmacokinetics of co-administered steady state digoxin. This study will also evaluate the safety and tolerability of the combined steady state administration of solifenacin, mirabegron and digoxin.

Condition or disease Intervention/treatment Phase
Healthy Subjects Pharmacokinetics Drug-Drug Interaction (DDI) Drug: Mirabegron Drug: Solifenacin Drug: Digoxin Phase 1

Detailed Description:
This study is comprised of two study sequences with 2 investigational periods in each sequence. There will be a wash-out period between each investigational period. Patients will be admitted to the clinic until discharged after each investigational period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: A Phase 1 Study to Evaluate the Effect of Steady State Solifenacin and Mirabegron on the Steady State Pharmacokinetics of Digoxin in Healthy Subjects
Study Start Date : March 2014
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Digoxin / digoxin + solifenacin and mirabegron
Digoxin alone then followed by digoxin with solifenacin and mirabegron
Drug: Mirabegron
oral
Other Names:
  • Myrbetriq
  • Betmiga
  • Betamis

Drug: Solifenacin
oral
Other Names:
  • solifenacin succinate
  • Vesikur
  • Vesicare

Drug: Digoxin
oral
Other Name: Lenoxin

Experimental: Digoxin + solifenacin and mirabegron / digoxin
Digoxin with solifenacin and mirabegron then followed by digoxin alone
Drug: Mirabegron
oral
Other Names:
  • Myrbetriq
  • Betmiga
  • Betamis

Drug: Solifenacin
oral
Other Names:
  • solifenacin succinate
  • Vesikur
  • Vesicare

Drug: Digoxin
oral
Other Name: Lenoxin




Primary Outcome Measures :
  1. Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: Cmax [ Time Frame: Day 10 ]
    Maximum concentration (Cmax)

  2. Pharmacokinetic parameter for digoxin (plasma) in the absence and presence of solifenacin and mirabegron: AUCtau [ Time Frame: Day 10 ]
    Area under the curve over a dosing interval (AUCtau)


Secondary Outcome Measures :
  1. Pharmacokinetic parameter for digoxin (plasma): Ctrough [ Time Frame: Days 7, 8 and 9 in each investigational period ]
    Concentration immediately prior to dosing at multiple dosing (Ctrough)

  2. Pharmacokinetic parameter for digoxin (plasma): tmax, CL/F, PTR [ Time Frame: Days 10 in each investigational period ]
    Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F), Peak-through ratio (PTR)

  3. Pharmacokinetic parameter for digoxin (urine): Aetau, CLR, Aetau% [ Time Frame: Day 10 in each investigational period ]
    Cumulative amount of drug excreted into urine, feces or bile from the time of dosing to the start of the next dosing interval (Aetau), renal clearance (CLR), percent of drug dose excreted into urine, feces or bile (Aetau) over the time interval between consecutive dosing (Aetau%)

  4. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Ctrough [ Time Frame: Days 7, 8 and 9 (1 investigational period per sequence only) ]
    Concentration immediately prior to dosing at multiple dosing (Ctrough)

  5. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cmax, AUCtau, tmax, CL/F [ Time Frame: Day 10 (1 investigational period per sequence only) ]
    Maximum concentration (Cmax), Area under the curve over a dosing interval (AUCtau), Time after dosing when Cmax occurs (tmax), apparent total systemic clearance after single or multiple extra-vascular dosing (CL/F)

  6. Pharmacokinetic parameter for solifenacin and mirabegron (plasma): Cpredose [ Time Frame: Day 1 (1 investigational period for only 1 treatment sequence) ]
    Concentration immediately prior to the first dose (Cpredose)

  7. Genotyping for CYP2D6 [ Time Frame: Day 1 ]
  8. Safety as assessed by adverse events, physical examination, vital signs, 12-lead ECG and laboratory tests [ Time Frame: Up to Day 11 in each investigational period (and at end of study visit, up to 9 days after) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subject has a body mass index range of 20.0 to 30.0 kg/m2, inclusive. The subject weighs at least 50 kg [screening].
  • Female subject must either:

    • Be of non-child bearing potential:

      1. post-menopausal (defined as at least 1 year without any menses) prior to screening, or
      2. documented surgically sterile
    • Or, if of childbearing potential,

      1. Agree not to try to become pregnant during the clinical study and for 28 days after the final study drug administration, and
      2. must have a negative urine/serum pregnancy test at screening and day -1,and
      3. if heterosexually active, agree to consistently use 2 forms of highly effective birth control starting at screening and throughout the clinical study period and for 28 days after the final study drug administration.
  • Female subject must agree not to breastfeed starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
  • Female subject must not donate ova starting at screening and throughout the clinical study period, and for 28 days after the final study drug administration.
  • Male subject and their female spouse/partners who are of childbearing potential must be using a highly effective form of contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the clinical study period and for 90 days after the final study drug administration.
  • Male subject must not donate sperm starting at screening and throughout the clinical study period and for 90 days after the final study drug administration
  • Subject agrees not to participate in another interventional study while participating in the present clinical study, defined as signing the informed consent form (ICF) until completion of the last study visit.

Exclusion Criteria:

  • Female subject who has been pregnant within 6 months prior to screening assessment or breast feeding within 3 months prior to screening.
  • Subject has a known or suspected hypersensitivity to solifenacin succinate, mirabegron, digoxin or any components of the formulations used.
  • Subject has any of the liver function tests (LFTs) (aspartate aminotransferase [AST], alanine aminotransferase [ALT], alkaline phosphatase [ALP], GGT, total bilirubin [TBL]) above the upper limit of normal (ULN). In such a case the assessment may be repeated once [day -1].
  • Subject has any clinically significant history of allergic conditions.
  • Subject has/had febrile illness or symptomatic, viral, bacterial (including upper respiratory infection), or fungal (non-cutaneous) infection within 1 week prior to day -1.
  • Subject has any clinically significant abnormality following the Investigator's review of the physical examination, ECG (e.g., any level of sinus node disease or atrioventricular defect) and protocol defined clinical laboratory tests (e.g., electrolyte abnormalities such as hypokalemia) at screening or day -1.
  • Subject has any history or evidence of any clinically significant cardiovascular, gastrointestinal, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major disease or malignancy, as judged by the medical Investigator.
  • Subject has a mean heart rate (HR) of < 50 or > 90 beats per minute (bpm); mean systolic BP >140 mmHg; mean diastolic BP > 90 mmHg at day-1 (vital sign measurements taken in triplicate after subject has been resting in supine position for 5 min; pulse will be measured automatically).
  • Subject has a mean QTc(F) interval of > 430 ms (for males) and > 450 ms (for females) at day-1. If the mean QTc(F) exceeds the limits above, 1 additional triplicate ECG can be taken. If this triplicate also gives abnormal result the subject should be excluded.
  • Subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias or torsade de pointes, structural heart disease, or a family history of Long QT Syndrome.
  • Subject has any clinically significant history of or risk of urinary retention, severe gastrointestinal condition (including toxic megacolon), myasthenia gravis or narrow-angle glaucoma.
  • Subject uses any prescribed or non-prescribed drugs (including vitamins, hormone replacement therapy or natural and herbal remedies [e.g., St. John's Wort]) in the 2 weeks prior to study drug administration, except for occasional use of paracetamol (up to 2 g/day).
  • Subject has a history of smoking more than 10 cigarettes (or equivalent amount of tobacco) per day within 3 months prior to admission to the clinical unit.
  • Subject has a history of drinking more than 21 units (14 units for females) of alcohol per week (1 unit = 10 g pure alcohol = 250 mL of beer [5] or 35 mL of spirits [35%] or 100 mL of wine [12%]) within 3 months prior to admission to the clinical unit.
  • Subject consumes grapefruit juice (more than 3 x 200 mL) or marmalade (more than 3 times) star fruit, Seville oranges or Seville orange juice containing products in the week prior to admission to the clinical unit until end of study visit (ESV), as reported by the subject.
  • Subject uses any drugs of abuse within 3 months prior to admission to the clinical unit.
  • Subject regularly uses of any inducer of metabolism (e.g., barbiturates, rifampin) in the 3 months prior to admission to the clinical unit.
  • Subject has significant blood loss, donated 1 unit (500 mL) of blood or more, or received a transfusion of any blood or blood products within 60 days or donated plasma within 7 days prior to clinic admission on day -1.
  • Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core (HBc) antibodies, hepatitis A virus (HAV) antibodies (Immunoglobulin M [IgM]), hepatitis C virus (HCV) antibodies or human immunodeficiency virus (HIV) 1+2 antibodies.
  • Subject participated in any clinical study or has been treated with any investigational drugs within 28 days prior to screening.
  • Subject is a vulnerable subject (e.g., subject kept in detention).
  • Subject is an employee of the Astellas Group or Contract Research Organization (CRO) involved in the clinical study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02127034


Locations
Layout table for location information
Germany
Parexel International GmbH
Berlin, Germany, 14050
Sponsors and Collaborators
Astellas Pharma Europe B.V.
Investigators
Layout table for investigator information
Study Director: Clinical Research Physician Astellas Pharma Europe B.V.

Layout table for additonal information
Responsible Party: Astellas Pharma Europe B.V.
ClinicalTrials.gov Identifier: NCT02127034    
Other Study ID Numbers: 178-CL-107
2013-004222-28 ( EudraCT Number )
First Posted: April 30, 2014    Key Record Dates
Last Update Posted: July 11, 2014
Last Verified: July 2014
Keywords provided by Astellas Pharma Inc ( Astellas Pharma Europe B.V. ):
Healthy subjects
Mirabegron
Solifenacin
Digoxin
Additional relevant MeSH terms:
Layout table for MeSH terms
Digoxin
Solifenacin Succinate
Mirabegron
Anti-Arrhythmia Agents
Cardiotonic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Urological Agents
Adrenergic beta-3 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents